BIOMEDCODE S.A.
A stranger
INFRAPLUS: Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
HORIZON EUROPE:
HORIZON-INFRA-2023-DEV-01
In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine...
2024-06-20 - 2027-05-31 | financed
2024-06-20 - 2027-05-31 | financed
INFRAFRONTIER2020: Towards enduring mouse resources and services advancing research into human health and disease
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
H2020:
H2020-INFRADEV-2016-2017
The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse...
2016-12-14 - 2021-12-31 | financed
2016-12-14 - 2021-12-31 | financed
BTCURE: BeTheCuRE
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP6:
BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
2011-04-01 - 2017-03-31 | financed
2011-04-01 - 2017-03-31 | financed
INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the...
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
financed
financed
BTCURE: BeTheCuRE
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
financed
financed
MASTERSWITCH: Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
Objective: To delineate the biological and molecular pathways that initiate and drive chronic inflammatory disease and to transform the know...
financed
financed
ADDRESS: Joint training and research network on Chromatin Dynamics and the DNA Damage Response
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
DNA is tightly wrapped around histones to form chromatin, a highly dynamic structure that can adopt different conformations with contrasting...
financed
financed
CodeAge: The role of Chronic DNA damage in Ageing and Age related pathology
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
Ageing is an inexorable homeostatic failure of largely unknown aetiology that leads to increased vulnerability to disease limiting the quali...
financed
financed
TARKINAID: Targeting Src family tyrosine kinases in chronic autoimmune and inflammatory diseases
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
participó en un
FP7:
The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase...
financed
financed
* No data from the current company are not available.